Eli Lilly And Co vs SoFi Technologies Inc — how do they compare? Eli Lilly And Co trades at $1,163 (market cap $1.02T), while SoFi Technologies Inc trades at $17.32 (market cap $21.82B). The key difference: Eli Lilly And Co is far larger — about 46.7× SoFi Technologies Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| LLY | SOFI | |
|---|---|---|
Market Cap | $1.02T | $21.82B |
Sector | Health | Financials |
52-Week High | $1.24K | $32.21 |
52-Week Low | $625.65 | $15.15 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SOFI Technologies trades at $17.07, down 1.22% with a bearish technical signal. The company shows strong revenue growth, reaching $3.61B in 2025 with consistent earnings beats, though net income declined to $481M. Analyst consensus is mixed with a $22.43 price target, while recent news highlights upcoming Q2 earnings and takeover speculation.
SOFI presents growth potential with 30% revenue guidance and digital platform expansion, but faces risks from negative operating cash flow and competitive pressures. The stock's current valuation at 38.4 P/E requires continued execution to justify upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →